Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
NanoRepro AG Develops and distributes rapid diagnostic self-tests for early disease detection.	Germany	NN6
NANOVIRICIDES, INC. Developing biomimetic nanomachines as broad-spectrum drugs to neutralize viral infections.	United States of America	NNVC
Nasus Pharma Ltd Develops powder-based intranasal drugs for rapid delivery in acute medical emergencies.	United States of America	NSRX
NATAC Develops sustainable plant extracts for nutraceutical, pharma, food, and animal nutrition industries.	Spain	NAT
Natera, Inc. Provides non-invasive cfDNA tests for oncology, women's health, and organ health.	United States of America	NTRA
Naturalendo Tech Co., Ltd Biotech R&D of natural ingredients for health and wellness solutions.	South Korea	168330
Naturland Holding PLC A Hungarian company providing full-scale pharmaceutical manufacturing from R&D to sales.	United Kingdom	NATUR
NEKTAR THERAPEUTICS Biopharma developing innovative medicines for autoimmune and inflammatory conditions.	United States of America	NKTR
NEOGEN CORP Provides diagnostic tests and genomics services for food, animal, and agricultural safety.	United States of America	NEOG
NEOGENOMICS INC Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.	United States of America	NEO